Study of the Transmission-Blocking Vaccine Pfs230D1-EPA/Matrix-M Against Malaria in Adults in Mali

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

October 22, 2021

Primary Completion Date

February 17, 2023

Study Completion Date

June 21, 2023

Conditions
Malaria,Falciparum
Interventions
BIOLOGICAL

Pfs230D1-EPA/Matrix-M Vaccine

Each single-use vial of Pfs230D1M-EPA contains 160 µg/mL of conjugated Pfs230D1M and 124 µg/mL or 143 µg/mL of conjugated EPA in 4 mM phosphate-buffered saline (PBS), in a volume of 0.5 mL. Each vial of Matrix-M1 contains saponin content of 0.375 mg/mL in PBS, at a pH of 7.2, in a final volume of 0.75 mL. Components will be combined in volumes defined in the protocol at point of use.

BIOLOGICAL

Verorab Rabies Vaccine

Verorab Rabies Vaccine is a purified inactivated rabies vaccine (Wistar rabies PM/WI 38 1503-3M strain) prepared on Vero cells. It is supplied as a powder and solvent for suspension for injection in a prefilled syringe. Before reconstitution, the powder is a white and homogeneous pellet. The solvent is a limpid solution.

Trial Locations (1)

Unknown

Malaria Research Training Center, Bamako

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novavax

INDUSTRY

collaborator

Malaria Research and Training Center, Bamako, Mali

OTHER

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT05135273 - Study of the Transmission-Blocking Vaccine Pfs230D1-EPA/Matrix-M Against Malaria in Adults in Mali | Biotech Hunter | Biotech Hunter